These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. A fresh look at tumor immunosurveillance and immunotherapy. Smyth MJ; Godfrey DI; Trapani JA Nat Immunol; 2001 Apr; 2(4):293-9. PubMed ID: 11276199 [TBL] [Abstract][Full Text] [Related]
10. Principles of tumor immunosurveillance and implications for immunotherapy. Ochsenbein AF Cancer Gene Ther; 2002 Dec; 9(12):1043-55. PubMed ID: 12522443 [TBL] [Abstract][Full Text] [Related]
11. [Immune response and cancer]. El Hage F; Abouzahr-Rifai S; Meslin F; Mami-Chouaib F; Chouaib S Bull Cancer; 2008 Jan; 95(1):57-67. PubMed ID: 18230571 [TBL] [Abstract][Full Text] [Related]
12. How do tumors actively escape from host immunosurveillance? Wilczyński JR; Duechler M Arch Immunol Ther Exp (Warsz); 2010 Dec; 58(6):435-48. PubMed ID: 20922572 [TBL] [Abstract][Full Text] [Related]
13. Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses. de Souza AP; Bonorino C Expert Rev Anticancer Ther; 2009 Sep; 9(9):1317-32. PubMed ID: 19761435 [TBL] [Abstract][Full Text] [Related]
14. Constitutive expression of TGF-bêta1, interleukin-6 and interleukin-8 by tumor cells as a major component of immune escape in human ovarian carcinoma. Toutirais O; Chartier P; Dubois D; Bouet F; Lévêque J; Catros-Quemener V; Genetet N Eur Cytokine Netw; 2003; 14(4):246-55. PubMed ID: 14715418 [TBL] [Abstract][Full Text] [Related]
15. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors. Khawli LA; Hu P; Epstein AL Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951 [TBL] [Abstract][Full Text] [Related]
16. [Immune tolerance and active suppression in oncology. Immunological principles and therapeutic options]. Stremmel C; Klein P; Hohenberger W Chirurg; 2002 Mar; 73(3):255-61. PubMed ID: 11963500 [TBL] [Abstract][Full Text] [Related]
17. Tumor immune escape mediated by indoleamine 2,3-dioxygenase. Zamanakou M; Germenis AE; Karanikas V Immunol Lett; 2007 Aug; 111(2):69-75. PubMed ID: 17644189 [TBL] [Abstract][Full Text] [Related]
18. Coexpression of CD40L and CD70 by semiallogenic tumor cells induces anti-tumor immunity. Cormary C; Hiver E; Mariamé B; Favre G; Tilkin-Mariamé AF Cancer Gene Ther; 2005 Dec; 12(12):963-72. PubMed ID: 15956983 [TBL] [Abstract][Full Text] [Related]
19. T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy. Tjin EP; Konijnenberg D; Krebbers G; Mallo H; Drijfhout JW; Franken KL; van der Horst CM; Bos JD; Nieweg OE; Kroon BB; Haanen JB; Melief CJ; Vyth-Dreese FA; Luiten RM Clin Cancer Res; 2011 Sep; 17(17):5736-47. PubMed ID: 21750202 [TBL] [Abstract][Full Text] [Related]
20. MHC class I antigens, immune surveillance, and tumor immune escape. Garcia-Lora A; Algarra I; Garrido F J Cell Physiol; 2003 Jun; 195(3):346-55. PubMed ID: 12704644 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]